Skip to main content
    H

    Humacyte Inc (HUMAW)

    Official site

    BIOTECHNOLOGY • NASDAQ

    $0.00
    +0.00 (+0.00%)

    Last updated: Aug 26, 2026 at 5:00 PM ET

    Humacyte Inc (HUMAW) Financials: Revenue, Profit and Cash Flow

    Updated Jun 30, 2026. Financial statements from company filings, amounts in US dollars.

    Humacyte reported revenue of $2.04M for the fiscal year ended Dec 31, 2025. That year, net income was -$40.83M with a net margin of -2003.6%, operating cash flow was -$105.04M and free cash flow was -$105.93M. The quarter ended Jun 30, 2026 had revenue of $406.00K and net income of -$36.80M.

    Revenue and Margins

    Over the 6 years to Dec 2025, revenue fell from $6.19M, a compound annual decline of 16.9%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$2.04MN/A-736.5%-5271.7%-2003.6%
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$1.56M+23.9%-427.5%-5404.3%-764.5%
    Dec 2021$1.26M-15.3%-4756.8%-6429.8%-2096.4%
    Dec 2020$1.49M-75.9%-3527.0%-4332.7%-4461.7%
    Dec 2019$6.19MN/A-1122.0%-1385.0%-1380.7%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$2.04M$0$0$1.56M$1.26M$1.49M$6.19M
    Cost of revenue$17.05M$7.19M$76.55M$8.26M$61.34M$54.08M$75.60M
    Gross profit-$15.01M-$7.19M-$76.55M-$6.69M-$60.08M-$52.59M-$69.42M
    Research and development$69.30M$88.60M$76.55M$63.26M$61.34M$54.08M$75.60M
    Operating income-$107.44M-$114.40M-$100.05M-$84.58M-$81.21M-$64.60M-$85.69M
    Net income-$40.83M-$148.70M-$110.78M-$11.96M-$26.48M-$66.52M-$85.42M
    EBITDA-$22.24MN/A-$96.46M$2.44M-$13.89M-$56.25M-$78.94M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$406.00K$495.00K$467.00K$753.00K$301.00K$517.00K$7.23M$0$0$0$10.79M$0
    Gross profit-$825.00K-$1.54M-$10.40M-$1.37M-$1.77M-$1.46M$3.61M-$1.81M-$1.82M-$1.79M-$3.38M-$1.31M
    Operating income-$27.00M-$28.93M-$30.84M-$24.39M-$29.73M-$23.18M-$28.09M-$30.23M-$29.50M-$26.58M-$26.18M-$24.62M
    Net income-$36.80M-$17.62M-$24.80M-$17.51M-$37.66M$39.14M-$20.94M-$39.20M-$56.66M-$31.90M-$25.11M-$26.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $37.87M by $12.63M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$116.37M$137.87M$128.22M$204.30M$286.53M$106.69M$168.69M
    Current assets$67.80M$47.86M$83.28M$154.21M$229.34M$41.45M$94.95M
    Cash and equivalents$50.50M$44.94M$80.45M$149.77M$217.50M$39.93M$93.71M
    Total liabilities$113.26M$190.54M$114.68M$87.37M$164.36M$36.02M$36.49M
    Short-term debt$2.43M$2.92M$2.56M$10.88M$2.03M$4.22M$3.07M
    Long-term debt$35.44MN/A$38.60M$20.34M$27.36M$822.00KN/A
    Shareholder equity$3.11M-$52.67M$13.55M$116.93M$122.17M$70.67M$132.20M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$138.09M$110.56M$116.37M$91.51M$138.79M$162.55M$137.87M$114.76M$138.28M$161.47M$128.22M$149.38M
    Total liabilities$106.83M$98.93M$113.26M$96.26M$134.74M$126.51M$190.54M$178.49M$166.57M$135.31M$114.68M$112.39M
    Cash and equivalents$79.90M$48.54M$50.50M$19.49M$38.03M$62.85M$44.94M$20.57M$93.56M$115.50M$80.45M$99.99M
    Shareholder equity$31.26M$11.62M$3.11M-$4.75M$4.05M$36.04M-$52.67M-$63.72M-$28.29M$26.15M$13.55M$36.99M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$105.04M-$98.12M-$73.31M-$71.13M-$81.19M-$55.57M-$71.79M
    Capital expenditures$884.00K$1.57M$2.28M$1.05M$220.00K$318.00K$8.13M
    Free cash flow-$105.93M-$99.69M-$75.58M-$72.18M-$81.41M-$55.89M-$79.91M
    Investing cash flow-$884.00K-$1.57M-$173.00K$4.84M-$8.22M-$268.00K-$8.13M
    Financing cash flow$61.49M$114.18M$4.51M-$1.45M$266.98M$2.05M-$74.00K
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$22.06M-$25.10M-$26.12M-$23.90M-$26.41M-$28.60M-$26.58M-$22.91M-$21.29M-$27.35M-$19.05M-$13.01M
    Capital expenditures$104.00K$175.00K$39.00K$49.00K$568.00K$228.00K$63.00K$934.00K$184.00K$391.00K$150.00K$493.00K
    Free cash flow-$22.16M-$25.28M-$26.16M-$23.95M-$26.98M-$28.83M-$26.64M-$23.84M-$21.48M-$27.74M-$19.20M-$13.50M
    Last 12 quarters

    Frequently Asked Questions About HUMAW

    What is Humacyte's annual revenue?

    Humacyte reported revenue of $2.04M for the fiscal year ended Dec 31, 2025.

    Is Humacyte profitable?

    No. Humacyte reported net income of -$40.83M for the fiscal year ended Dec 31, 2025, with a net margin of -2003.6%.

    How much free cash flow does HUMAW generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$105.04M minus capital expenditures of $884.00K produced free cash flow of -$105.93M.

    How much debt does Humacyte have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $35.44M, short-term debt of $2.43M and cash and equivalents of $50.50M.

    What is HUMAW's profit margin?

    For the fiscal year ended Dec 31, 2025, Humacyte reported gross margin of -736.5%, operating margin of -5271.7% and net margin of -2003.6%.